Tango Therapeutics Inc TNGX

$25.50 +0.65 (2.62%)

Valuation

Market cap
4,321,103,000
Revenue TTM
$62,380,000
Net income TTM
$-101,590,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-162.86%
Debt to equity
0.00

Trading

Volume
2,706,100
Avg volume
3,807,156
Day's range
$23.66 – $25.58
Shares out
169,455,000
Stochastic %K
84%
Beta
1.26
Analysts
Strong Buy
Price target
$44.75

Price

Company profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for t...

Show more

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 320 4900
Website
https://www.tangotx.com
Address
201 Brookline Avenue, Suite 901, Boston, United States

Latest news

Stocktwits

AXLFI_HQ Nov 14, 12:14 AM
The most recent Relative Strength signal on $TNGX triggered on 2026-11-13. The expected return for the selected horizon is +37.90% with a historical profit probability of +69.23%. Learn more: https://axlfi.com/factors/stock/TNGX/relative_strength/daily?pass=eyJrIjoibGluayIsImUiOjE3OTQ3ODgwNTR9.pse7rL7cUmEKE-hnpKOucw
0 replies
mohamettarik Nov 13, 8:00 PM
$TNGX Funding and dilution risk: Negative operating cash flow and higher-than-expected research and general expenses increase funding needs and raise the prospect of future share dilution. Small data sets: The efficacy findings come from relatively small patient cohorts, so they may not generalize to larger, more diverse populations or predict late-stage trial results. Analyst objectivity: Investment banking and other firm relationships could create conflicts of interest that bias analyst coverage.
0 replies
Alt_Fuel Nov 13, 12:46 PM
$VSTM $RVMD $TNGX $ERAS Positioning relative to the highlighted shift Verastem’s strategy aligns with Doepke’s view that combinations are the way forward: strong single-agent activity with a selective G12D inhibitor (potentially preferred for that large subgroup over pan-RAS agents due to selectivity/tolerability) plus deliberate combo trials in 1L and later lines. Analysts have noted its [ Verastems] data as competitive or superior in the G12D subset compared with pan-RAS agents like daraxonrasib in certain cross-trial views. Doepke himself has posted positively on the VS-7375 updates (including the 50% 2L ORR and Phase 3 plans) in the context of RVMD and ERAS. Verastem is one of several companies (alongside Revolution, Tango, Erasca, and others) driving this RAS-focused, combination-heavy wave in PDAC. Cash position was strengthened by a recent $250M offering, supporting continued development. https://x.com/i/grok?conversation=2121221416158720203
0 replies
AXLFI_HQ Nov 13, 12:45 AM
The most recent ROC Curve signal on $TNGX triggered on 2026-11-12. The expected return for the selected horizon is +69.12% with a historical profit probability of +60.00%. Learn more: https://axlfi.com/factors/stock/TNGX/roc_curve/daily?pass=eyJrIjoibGluayIsImUiOjE3OTQ3MDM1MjR9.m1ybo7CcSWJhAo7m7aOj8Q
0 replies
mohamettarik Nov 12, 3:06 PM 0 replies
kundakunda Nov 12, 3:48 AM
$TNGX lots of cash, 2027 catalyst, possible buyout target and now reclaim of the 200ma
0 replies
topstockalerts Nov 11, 9:48 PM
JPMorgan reiterated its Overweight rating on Tango Therapeutics and maintained the biotech company on its Analyst Focus List following Q3 results that came in line with expectations. Analyst Brian Cheng remains positive ahead of several clinical and regulatory catalysts expected through year-end and early 2027. The company's pivotal Phase 3 combination trial of vopi and darax for first-line pancreatic ductal adenocarcinoma remains on track to begin in the first half of 2027, while regulatory discussions continue regarding the potential approval pathway for second-line treatment. Key catalysts include January updates on the brain-penetrant ’456 monotherapy program across indications such as non-small cell lung cancer and glioblastoma, as well as additional vopi data in lung cancer. JPMorgan also highlighted potential expansion into other tumor types and further development of PRMT5 therapies. $TNGX $JPM
1 replies
mohamettarik Nov 11, 6:46 PM
$TNGX @Belisimo they all say the same... dont make drama... i am coming from this industry and i can see the good from the devil... i worked in pharma comapnies where marketing managers were trying to find drawbacks in new cometitiors and maximiz its message to threaten HCPs of using it, despit the benefit...leaving helping people aside :D ... i said from begining you can be eaisly cheated... see you at $10 or $6 sooon ... i wish to hear you again . ... will mention you
0 replies